Your browser doesn't support javascript.
loading
Advances in gene therapy for hemophilia.
Robles-Rodriguez, Olivia A; Pe Rez-Trujillo, Jose J; Villanueva-Olivo, Arnulfo; Villarreal-Martinez, Laura; Marfil-Rivera, Luis J; Rodriguez-Rocha, Humberto; Garcia-Garcia, Aracely; Saucedo-Cardenas, Odila; Loera-Arias, Maria J; Oca-Luna, Roberto Montes DE.
Afiliación
  • Robles-Rodriguez OA; Departamento de Histologia, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, C.P. 64460 Monterrey, Mexico.
J Biosci ; 452020.
Article en En | MEDLINE | ID: mdl-32661215
Hemophilia is a hereditary disorder that can be life-threatening in individuals who have severe spontaneous bleeding resulting from minor trauma or surgery. Although replacement therapy of the missing exogenous factor has improved patients' quality of life, it has not been possible to establish a long-term treatment. Due to the severity of the disease and the need for repetitive doses throughout the patient's life, replacement therapy has become a high-cost treatment option; therefore, the development of self-sustainable long-term therapies is critical. Hemophilia is a good candidate for gene therapy because it is a monogenic disease that can be counteracted by expression of the missing factor. In this article, we review some of the most relevant advances in gene therapy for this illness.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Terapia Genética / Hemofilia A / Hemorragia Límite: Humans Idioma: En Revista: J Biosci Año: 2020 Tipo del documento: Article País de afiliación: México
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Terapia Genética / Hemofilia A / Hemorragia Límite: Humans Idioma: En Revista: J Biosci Año: 2020 Tipo del documento: Article País de afiliación: México